IGF1 and cancer: The strategies to target IGF in cancer consist of (1) reducing circulating ligand levels or bioactivity, (2) blocking receptor function using receptor-specific antibodies or small-molecule tyrosine kinase inhibitors, and (3) activating AMP-activated protein kinase (AMPK) (see Figure 1).